公开(公告)号：US20140161819A1

公开(公告)日：2014-06-12

申请号：US14098710

申请日：2013-12-06

申请人： The Regents of the University of California ,  SANOFI

发明人： Byron C. Hann ,  Blake Tomkinson ,  Thomas G. Martin, III ,  Blake T. Aftab

IPC分类号： A61K39/395 ,  A61K31/45 ,  A61K45/06

CPC分类号： A61K39/39558 ,  A61K31/37 ,  A61K31/45 ,  A61K31/454 ,  A61K31/573 ,  A61K31/616 ,  A61K31/727 ,  A61K45/06 ,  A61K31/00 ,  A61K2300/00

摘要： Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

摘要翻译： 本文公开了包含抗CD38抗体和来那度胺化合物的组合物和试剂盒。 还公开了在具有组合物和试剂盒的受试者中治疗癌症如多发性骨髓瘤的方法。

公开(公告)号：US10342869B2

公开(公告)日：2019-07-09

申请号：US14098710

申请日：2013-12-06

申请人： SANOFI ,  The Regents of the University of California

发明人： Byron C. Hann ,  Blake Tomkinson ,  Thomas G. Martin, III ,  Blake T. Aftab

IPC分类号： A61K39/395 ,  A61K31/45 ,  A61K45/06 ,  A61K31/37 ,  A61K31/454 ,  A61K31/573 ,  A61K31/616 ,  A61K31/727

摘要： Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and lenalidomide compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.

公开(公告)号：US20180022814A1

公开(公告)日：2018-01-25

申请号：US15479500

申请日：2017-04-05

申请人： SANOFI

发明人： Antoine Deslandes ,  Krzysztof J. Grzegorzewski ,  Marie-Laure Ozoux ,  Blake Tomkinson

IPC分类号： C07K16/28 ,  A61K31/573 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/2896 ,  A61K31/573 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  A61K2300/00

摘要： The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

公开(公告)号：US20150118251A1

公开(公告)日：2015-04-30

申请号：US14529719

申请日：2014-10-31

申请人： SANOFI

发明人： Antoine Deslandes ,  Krzysztof J. Grzegorzewski ,  Marie-Laure Ozoux ,  Blake Tomkinson

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61K31/573

CPC分类号： C07K16/2896 ,  A61K31/573 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  A61K2300/00

摘要： The present disclosure concerns an antibody that specifically binds CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose of about 20 mg/kg or below. In one embodiment, the medicament is for treating CD38+ multiple Myeloma in humans.

摘要翻译： 本公开涉及特异性结合CD38的抗体，其能够通过诱导凋亡，抗体依赖性细胞介导的细胞毒性（ADCC）和补体依赖性细胞毒性来杀死CD38 +细胞。 所公开的抗体可以用作药物或制备药物，其中抗体以约20mg / kg或更低的安全治疗剂量施用于人受试者。 在一个实施方案中，所述药物用于治疗人类中的CD38 +多发性骨髓瘤。